Device Trial Radar · NCT02107222
The PALP™-COPD Trial (Low-Flow CO2-Removal (ECCO2-R) in Exacerbated COPD)
Last checked: Nov 21, 2026Latest source record: Apr 1, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Sponsor
- Lead sponsor
- Maquet Cardiopulmonary GmbHNot on our public-company list
- Sponsor type
- Industry
- First posted
- Apr 8, 2014
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Multicenter, Randomized, Controlled Trial to Determine Safety and Efficacy of Pump Assisted Lung Protection (PALP™) for Low Flow Carbon Dioxide (CO2) Removal in Conjunction with Liberation from Mechanical Ventilation Compared to Mechanical Ventilation Alone in Patients with COPD Exacerbation and Respiratory Failure
Conditions
- COPD
- Chronic Obstructive Pulmonary Disease
Interventions
CO2-Removal (PALP-Device/MaquetCP)Device
extracorporeal circuit to remove CO2 out of the blood
Primary outcomes
What the sponsor says the trial is designed to measure.
- Difference in time of mechanical ventilationTime frame: 720 hours
Locations
1 site in 1 country. Site status is shown where the registry gives one.
MAQUET Cardiopulmonary AG
Rastatt, Germany
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.